Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/3/2024 | $135.00 | Outperform | Oppenheimer |
| 7/30/2024 | $130.00 | Outperform | RBC Capital Mkts |
| 2/22/2022 | $180.00 → $130.00 | Buy | Benchmark |
| 2/18/2022 | $185.00 → $165.00 | Overweight | Barclays |
| 9/22/2021 | $174.00 → $180.00 | Overweight | Barclays |
| 7/30/2021 | $200.00 → $190.00 | Buy | Roth Capital |
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will present at the Stifel 2024 Healthcare Conference in New York on Tuesday, November 19, 2024, at 12:40 p.m. Eastern Time. Management is scheduled to host one-on-one meetings with investors and attendees during the conference. Investors interested in arranging one-on-one meetings should contact their Stifel representative. About Ligand Pharmaceuticals Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing
Third quarter performance driven by strong portfolio royalty revenue growth 2024 full year revenue guidance increased to $160 million - $165 million (previously $140 million - $157 million) and core adjusted earnings per diluted share1 increased to $5.50 - $5.70 (previously $5.00 - $5.50) Company to hold Investor and Analyst Day in Boston on December 10, 2024 Conference call begins at 8:30 a.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Easter
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will host an Investor and Analyst Day in Boston on Tuesday, December 10, 2024 from 10:30 a.m. to 12:00 p.m. Eastern Time. The in-person event will include presentations from Ligand's senior management team highlighting the company's strategy, investment activity, royalty portfolio, and long-term financial outlook. A live question and answer session will follow the formal presentation. Investors and analysts can register for the event here. A live webcast of the event will be accessible through Ligand's Investor Relations website at investor.ligand.com. A webcast replay will be available following the conclusion of t
Oppenheimer initiated coverage of Ligand Pharma with a rating of Outperform and set a new price target of $135.00
RBC Capital Mkts initiated coverage of Ligand Pharma with a rating of Outperform and set a new price target of $130.00
Benchmark reiterated coverage of Ligand Pharmaceuticals with a rating of Buy and set a new price target of $130.00 from $180.00 previously
4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
Third quarter performance driven by strong portfolio royalty revenue growth 2024 full year revenue guidance increased to $160 million - $165 million (previously $140 million - $157 million) and core adjusted earnings per diluted share1 increased to $5.50 - $5.70 (previously $5.00 - $5.50) Company to hold Investor and Analyst Day in Boston on December 10, 2024 Conference call begins at 8:30 a.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Easter
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report third quarter 2024 financial results before the opening of the U.S. financial markets on Thursday, November 7, 2024. The company will hold a conference call that same day beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and Webcast Information Date: Thursday, November 7, 2024 Time: 8:30 a.m. ET (5:30 a.m. PT) Conference Call: (888) 596-4144 (U.S. & Canada) (646) 968-2525 (International) Conference ID is 8755336 Webcast: Live and replay webcasts of t
Conference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti
4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
10-Q - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
8-K - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
10-Q - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
Craig-Hallum analyst Matt Hewitt maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $135 to $140.
HC Wainwright & Co. analyst Joseph Pantginis reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and maintains $144 price target.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it has entered into a definitive agreement to acquire APEIRON Biologics AG, which holds royalty rights to QARZIBA® (dinutuximab beta) for the treatment of high-risk neuroblastoma, for $100 million in cash. In addition, Ligand will pay APEIRON shareholders additional consideration based on future commercial and regulatory events, including up to $28 million if QARZIBA royalties exceed certain predetermined thresholds by either 2030 or 2034, respectively. APEIRON is a private biopharmaceutical company based in Vienna, Austria. The company co-developed QARZIBA for the treatment of high-risk neuroblastoma in patients aged 12
SC 13G/A - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)
SC 13G - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)
SC 13G/A - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)
WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced the appointment of Matthew E. Korenberg as Chief Financial Officer, effective immediately. Mr. Korenberg is a seasoned operational and financial leader with more than 27 years of senior executive experience in biotech companies and healthcare investment banking. Throughout his career, he has focused on capital raising, partnering and licensing deals, acquisitions, as well as overseeing p
Leading Antibody Discovery Technologies Enable Development of Innovative Therapeutics Regular-way Trading of OABI Begins November 2, 2022 on Nasdaq OmniAb, Inc. (NASDAQ:OABI) today announced the completion of the expected tax-free spin-off from Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and the subsequent business combination with Avista Public Acquisition Corp. II (NASDAQ:AHPA), resulting in OmniAb becoming an independent publicly traded company. Based on actual redemptions and estimated transaction expenses, OmniAb expects to have approximately $95 million in cash at closing. OmniAb will begin regular-way trading November 2, 2022 on Nasdaq under the stock ticker symbol "OABI." "
LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces the appointment of Paul Maier as Non-Executive Director of the Board. Mr Maier will also be a member of 4D's Audit and Risk Committee and will serve as the Company’s “audit committee financial expert” under SEC and Nasdaq rules. “With over 25 years of extensive senior operational, international and financial management experience in the pharmaceutical and biotechnology industry, Paul will be able to provide 4D pharma with invaluable insights as we continue to execute